1.24
1.64%
+0.02
AvroBio Inc stock is currently priced at $1.24, with a 24-hour trading volume of 36,535.
It has seen a +1.64% increased in the last 24 hours and a -3.88% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.23 pivot point. If it approaches the $1.26 resistance level, significant changes may occur.
AvroBio Inc Stock (AVRO) Financials Data
AvroBio Inc (AVRO) Net Income 2024
AVRO net income (TTM) was $12.16 million for the quarter ending December 31, 2023, a +111.48% increase year-over-year.
AvroBio Inc (AVRO) Cash Flow 2024
AVRO recorded a free cash flow (TTM) of -$63.20 million for the quarter ending December 31, 2023, a +35.16% increase year-over-year.
AvroBio Inc (AVRO) Earnings per Share 2024
AVRO earnings per share (TTM) was $0.27 for the quarter ending December 31, 2023, a +111.20% growth year-over-year.
AvroBio Inc Stock (AVRO) Latest News
About AvroBio Inc
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Cap:
|
Volume (24h):